Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5205723
Max Phase: Preclinical
Molecular Formula: C72H84Cl2F5N9O13
Molecular Weight: 1449.41
Associated Items:
ID: ALA5205723
Max Phase: Preclinical
Molecular Formula: C72H84Cl2F5N9O13
Molecular Weight: 1449.41
Associated Items:
Canonical SMILES: COc1cc(C(=O)NCCOCCOCCOCCOCCOCCOCCOCCNC(=O)c2ccc(-c3ccc(N4CCN(C)CC4)c(NC(=O)c4c[nH]c(=O)cc4C(F)(F)F)c3)cc2)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Standard InChI: InChI=1S/C72H84Cl2F5N9O13/c1-70(2,3)43-61-71(45-80,53-16-15-50(73)41-56(53)75)63(51-7-6-8-55(74)64(51)76)65(86-61)69(93)84-57-17-13-49(40-60(57)94-5)67(91)82-20-26-96-28-30-98-32-34-100-36-38-101-37-35-99-33-31-97-29-27-95-25-19-81-66(90)47-11-9-46(10-12-47)48-14-18-59(88-23-21-87(4)22-24-88)58(39-48)85-68(92)52-44-83-62(89)42-54(52)72(77,78)79/h6-18,39-42,44,61,63,65,86H,19-38,43H2,1-5H3,(H,81,90)(H,82,91)(H,83,89)(H,84,93)(H,85,92)/t61-,63-,65+,71-/m0/s1
Standard InChI Key: RGUFFFFIJCCRTF-FDVGVURUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1449.41 | Molecular Weight (Monoisotopic): 1447.5486 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Dölle A, Adhikari B, Krämer A, Weckesser J, Berner N, Berger LM, Diebold M, Szewczyk MM, Barsyte-Lovejoy D, Arrowsmith CH, Gebel J, Löhr F, Dötsch V, Eilers M, Heinzlmeir S, Kuster B, Sotriffer C, Wolf E, Knapp S.. (2021) Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders., 64 (15.0): [PMID:33980013] [10.1021/acs.jmedchem.1c00146] |
Source(1):